Quercetin for the treatment of COVID-19 patients: A systematic review and meta-analysis

Rev Med Virol. 2023 Mar;33(2):e2427. doi: 10.1002/rmv.2427. Epub 2023 Feb 13.


Currently approved therapies for COVID-19 are mostly limited by their low availability, high costs or the requirement of parenteral administration by trained medical personnel in an in-hospital setting. Quercetin is a cheap and easily accessible therapeutic option for COVID-19 patients. However, it has not been evaluated in a systematic review until now. We aimed to conduct a meta-analysis to assess the effect of quercetin on clinical outcomes in COVID-19 patients. Various databases including PubMed, the Cochrane Library and Embase were searched from inception until 5 October 2022 and results from six randomized controlled trials (RCTs) were pooled using a random-effects model. All analyses were conducted using RevMan 5.4 with odds ratio (OR) as the effect measure. Quercetin decreased the risk of intensive care unit admission (OR = 0.31; 95% confidence interval (CI) 0.10-0.99) and the incidence of hospitalisation (OR = 0.25; 95% CI 0.10-0.62) but did not decrease the risk of all-cause mortality and the rate of no recovery. Quercetin may be of benefit in COVID-19 patients, especially if administered in its phytosome formulation which greatly enhances its bioavailability but large-scale RCTs are needed to confirm these findings.

Keywords: COVID-19; SARS-CoV-2; flavonol; quercetin.

Publication types

  • Meta-Analysis
  • Systematic Review
  • Review

MeSH terms

  • COVID-19*
  • Hospitalization
  • Humans
  • Quercetin


  • Quercetin